Dyadic: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 12, 2026, Dyadic (NASDAQ:DYAI) announced a strategy shift toward larger strategic partnerships to scale its protein production platforms. Long-term investors care because Dyadic lacks the capital to fund independent manufacturing, making external licensing deals the primary driver of future revenue. Three things management said stand out.

1. Direct Product Sales Face Extended Customer Qualification Timelines

Customer evaluations in cell culture media require extensive testing to prove product consistency before switching suppliers. That dynamic delays the conversion of sample requests into recurring sales.

Our direct commercial sales remain modest, and customer qualification and adoption are taking longer than we originally anticipated.
-- Joseph Hazelton, President and Chief Operating Officer

2. Management Prioritizes Capital-Efficient Partnerships Over In-House Scaling

Dyadic chooses to license its production systems to established partners rather than funding stand-alone manufacturing infrastructure. Partnering with companies that own distribution networks reduces capital requirements while expanding market reach.

Rather than independently funding the development and commercialization of every product, we believe greater value can be created by partnering with companies that have the capital, manufacturing infrastructure, and commercial capabilities to bring our technologies and products to market at scale.
-- Joseph Hazelton, President and Chief Operating Officer

3. Externally Funded Programs Validate Biopharmaceutical Platform Yields

Grants from third-party foundations fund antibody testing while demonstrating high production yields in C1, Dyadic's proprietary fungal expression platform for biopharmaceuticals. High yields and comparable biological performance help validate the system for commercial drug developers.

Under our approximately $3.1 million Gates funded program C1 achieved productivity yields of approximately 12.1 grams per liter for RSV monoclonal antibody RSM01, and 13.2 grams per liter for malaria monoclonal antibody MAM01 in 7-day fermentations.
-- Mark A. Emalfarb, Chief Executive Officer

Looking Ahead

Third-party testing is advancing across biopharmaceutical and nutritional programs, showing platform versatility. Dyadic relies on strain-optimization capabilities and partner distribution networks, while management tracks customer-qualification discipline and manufacturing economics.

While additional validation and development remains necessary, the ongoing animal studies rapid development milestones, and expanding collaborations continue to strengthen the technical foundation and potential strategic value of C1.
-- Mark A. Emalfarb, Chief Executive Officer

Commercial scaling hinges on external capital and partner capabilities to convert platform validation into recurring revenue.

Our objective is to build on the technical and commercial foundation we have established and identify the most effective path to realize its value.
-- Joseph Hazelton, President and Chief Operating Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.